Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Itraconazole
Drug ID BADD_D01217
Description One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.
Indications and Usage For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.
Marketing Status approved; investigational
ATC Code J02AC02
DrugBank ID DB01167
KEGG ID D00350
MeSH ID D017964
PubChem ID 55283
TTD Drug ID D0V4IB
NDC Product Code 22568-1108; 53069-0450; 59349-0012; 65015-624; 65162-630; 60592-318; 62991-3078; 72761-019; 50268-450; 50458-290; 10147-0150; 67835-5043; 46708-204; 49884-239; 60687-299; 49452-3845; 51552-0920; 70771-1208; 17511-114; 71747-002; 13668-463; 67877-454; 12578-299; 38779-2759; 58032-0110; 66039-815; 62332-204; 65162-087; 69339-159; 10147-1700; 71052-301; 70518-2872; 70518-3559; 10695-064; 50546-462; 31722-006; 51862-462; 68382-697; 70518-3264; 66577-044; 16714-743; 16729-271; 50458-295
UNII 304NUG5GF4
Synonyms Itraconazole | R-51211 | R 51211 | R51211 | Sporanox | Orungal
Chemical Information
Molecular Formula C35H38Cl2N8O4
CAS Registry Number 84625-61-6
SMILES CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C 7=C(C=C(C=C7)Cl)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Atrioventricular block02.03.01.0020.005345%Not Available
Back pain15.03.04.005--
Bacteriuria11.02.01.014; 20.08.02.015--Not Available
Benign prostatic hyperplasia21.04.02.0010.004008%Not Available
Bladder pain20.02.02.001--Not Available
Blindness transient06.02.10.006; 17.17.01.0040.002672%Not Available
Blister23.03.01.001; 12.01.06.0020.005345%Not Available
Blood creatine phosphokinase increased13.04.01.001--
Blood creatinine increased13.13.01.004--
Blood lactate dehydrogenase increased13.04.02.002--
Blood triglycerides increased13.12.03.001--Not Available
Blood urea increased13.13.01.006--Not Available
Body temperature increased13.15.01.001--Not Available
Bradycardia02.03.02.0020.017370%Not Available
Breast pain21.05.05.003--
Bronchitis22.07.01.001; 11.01.09.001--
Bronchospasm22.03.01.004; 10.01.03.012--
Bursitis12.04.03.010; 15.04.01.001--Not Available
Cardiac arrest02.03.04.0010.018706%
Cardiac failure02.05.01.0010.062799%
Cardiac failure acute02.05.01.0050.004008%Not Available
Cardiac failure congestive02.05.01.0020.024051%Not Available
Cardiomegaly02.04.02.0010.004008%Not Available
Cardiovascular disorder24.03.02.009; 02.11.01.0100.002672%Not Available
Cerebrovascular disorder24.03.05.002; 17.08.02.0020.002672%Not Available
Chest discomfort22.12.02.002; 08.01.08.019; 02.02.02.0090.008017%Not Available
Chest pain08.01.08.002; 02.02.02.011; 22.12.02.003--Not Available
Chills15.05.03.016; 08.01.09.001--
Cholestasis09.01.01.0010.013362%Not Available
Chromaturia20.02.01.0020.004008%
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 12 Pages